A marine microbiome antifungal targets urgent-threat drug-resistant fungi
Marine bacteria produce a plethora of natural products that often have unusual chemical structures and corresponding reactivity, which sometimes translate into a valuable biological function. Zhang et al. used a metabolomic screen to zero in on microbial strains from the microbiome of a sea squirt t...
Saved in:
Published in | Science (American Association for the Advancement of Science) Vol. 370; no. 6519; pp. 974 - 978 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
The American Association for the Advancement of Science
20.11.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Marine bacteria produce a plethora of natural products that often have unusual chemical structures and corresponding reactivity, which sometimes translate into a valuable biological function. Zhang
et al.
used a metabolomic screen to zero in on microbial strains from the microbiome of a sea squirt that produces a high diversity of chemical structures. They then screened these molecules for inhibition of fungi (see the Perspective by Cowen). A polycyclic molecule dubbed turbinmicin possessed potent antifungal activity against the multidrug-resistant fungal pathogens
Candida auris
and
Aspergillus fumigatus
. Preliminary mechanism-of-action and mouse toxicity studies suggest that this molecule works though a fungus-specific pathway and is well tolerated at therapeutic doses.
Science
, this issue p.
974
; see also p.
906
A natural product from a marine bacterium shows selective activity against fungal pathogens.
New antifungal drugs are urgently needed to address the emergence and transcontinental spread of fungal infectious diseases, such as pandrug-resistant
Candida auris.
Leveraging the microbiomes of marine animals and cutting-edge metabolomics and genomic tools, we identified encouraging lead antifungal molecules with in vivo efficacy. The most promising lead, turbinmicin, displays potent in vitro and mouse-model efficacy toward multiple-drug–resistant fungal pathogens, exhibits a wide safety index, and functions through a fungal-specific mode of action, targeting Sec14 of the vesicular trafficking pathway. The efficacy, safety, and mode of action distinct from other antifungal drugs make turbinmicin a highly promising antifungal drug lead to help address devastating global fungal pathogens such as
C. auris. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally to this work. Author contributions: Consistent with CRediT taxonomy, the roles of contributing authors are as follows: Conceptualization: T.S.B., D.R.A., C.R.C., and W.T.; methodology: F.Z., M.Z., D.R.B., J.S.P., J.N., J.P., G.E.A., S.C., K.B.,I.A.G., C.Z., and L.G.; software: S.C., J.P., T.S.B., S.S.E., and J.S.P.; validation: I.A.G., F.Z., M.Z., D.R.B., A.A., D.R.A., and M.G.C.; formal analysis: F.Z., M.Z., S.S.E., J.S.P., J.N., G.E.A., J.F., A.A., and M.G.C.; investigation: F.Z., M.Z., S.S.E., C.Z., H.S., L.G., and A.A.; resources: D.R.B., S.S.E., G.E.A., S.C., K.B., H.S., and I.A.G.; data curation: F.Z., M.Z., G.E.A., W.T., C.R.C., S.R.R., A.A., D.R.A., and T.S.B.; writing—original draft: F.Z., S.R.R., M.Z., T.S.B., and D.R.A.; writing—review and editing: F.Z., J.F., H.S., J.S.P., C.R.C., S.R.R., A.A., D.R.A., and T.S.B.; visualization: T.S.B., D.R.A., C.R.C., and A.A.; supervision: T.S.B., D.R.A., C.R.C., and W.T.; project administration: D.R.A., T.S.B., and W.T.; and funding acquisition: D.R.A., C.R.C., T.S.B., and A.A. |
ISSN: | 0036-8075 1095-9203 1095-9203 |
DOI: | 10.1126/science.abd6919 |